

Substitutions at Methionine 220 in the 14 α -Sterol Demethylase (Cyp51A) of *Aspergillus fumigatus* Are Responsible for Resistance In Vitro to Azole Antifungal Drugs

E. Mellado,* G. Garcia-Effron, L. Alcazar-Fuoli, M. Cuenca-Estrella, and J. L. Rodriguez-Tudela

Servicio de Micología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain

Received 3 March 2004/Returned for modification 21 March 2004/Accepted 1 April 2004

Five clinical isolates of *Aspergillus fumigatus* that exhibited similar patterns of reduced susceptibility to itraconazole and other triazole drugs were analyzed. Sequence analysis of genes (*cyp51A* and *cyp51B*) encoding the 14 α -sterol demethylases revealed that all five strains harbored mutations in *cyp51A* resulting in the replacement of methionine at residue 220 by valine, lysine, or threonine. When the mutated *cyp51A* genes were introduced into an *A. fumigatus* wild-type strain, the transformants exhibited reduced susceptibility to all triazole agents, confirming that the mutations were responsible for the resistance phenotype.

Aspergillus fumigatus is one of the most prevalent airborne fungal pathogens causing infection worldwide, with high mortality and morbidity in the immunocompromised host (14). Although *A. fumigatus* is intrinsically resistant to fluconazole, the newer triazoles such as itraconazole (ITC), posaconazole (POS), and voriconazole (VRC) are active both in vitro and in vivo against this species (2, 11, 24). However, a number of *A. fumigatus* isolates with in vitro ITC resistance have been described previously (1, 4, 8, 9, 16, 19, 20); in some cases, the resistance detected in vitro has been confirmed in animal models of infection (3, 7). Resistance to VRC has been recently detected in clinical and laboratory strains (E. Manavathu, I. Baskaran, S. Krishnan, G. Alangaden, and P. Chandrasekar, Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., abstr. M-471, page 444, 2003, and E. Manavathu, A. Espinel-Ingroff, G. Alangaden, and P. Chandrasekar, Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., abstr. M-392, page 440, 2003). In addition, it appears that some clinical *Aspergillus* strains are starting to exhibit reduced susceptibility resulting in high drug MICs when new triazole agents such as POS and ravuconazole (RVC) are tested (19, 24).

The triazoles inhibit the ergosterol biosynthesis pathway via the inhibition of 14 α -sterol demethylase (Cyp51), an enzyme that removes the methyl group at position C-14 of precursor sterols. In *A. fumigatus*, there are two distinct but related Cyp51 proteins encoded by *cyp51A* and *cyp51B* (18). Two molecular mechanisms of resistance to azoles have been proposed in *A. fumigatus*: the first is reduced intracellular accumulation due to either increased expression of efflux pumps (8, 30) or reduced penetration of the drug (15). The other mechanism of resistance is through the modification of Cyp51 (8, 22). To date the most prevalent mechanism of resistance in *A. fumigatus* appears to be the modification of Cyp51, specifically mutations

in *cyp51A*. These mutations, in both clinical strains and laboratory-generated spontaneous mutants, have been associated with two different susceptibility profiles: (i) cross-resistance to ITC and POS has been associated with amino acid substitutions at glycine 54 (G54) (9, 16, 20); (ii) cross-resistance to VRC and RVC has been associated with amino acid substitutions at G448 (Manavathu et al., 43rd ICAAC, abstr. M-471). A third pattern of azole resistance was recently reported (9, 19). This new pattern is characterized by high ITC, VRC, RVC, and POS MICs. The majority of the strains exhibiting this susceptibility profile harbor amino acid substitutions at methionine 220 (M220), an area of Cyp51A that was not previously associated with amino acid substitutions causing reduced susceptibility to azoles (9, 16, 20).

The objective of this work was to determine whether the amino acid substitutions at M220 were sufficient to confer reduced susceptibility to azoles in *A. fumigatus*. To this end, *cyp51A* alleles encoding the different point mutations were introduced into a wild-type (azole-susceptible) *A. fumigatus* strain (CM-237); all three amino acid substitutions conferred reduced susceptibility to azoles.

Fungal strains and antifungal susceptibility testing. Eight clinical *A. fumigatus* strains from the Mycelial Collection of the Spanish National Centre for Microbiology (CNM-CM) were analyzed (Table 1). (i) Strains for which all azole drugs exhibited elevated MICs were as follows: CNM-CM-1252 (AF-90), CNM-CM-1245 (AF-91), CNM-CM-2158 (AF-1422), CNM-CM-2159 (F/6919), and CNM-CM-2164 (SO/3829). (ii) Strains susceptible to all four triazoles (drug MICs \leq 0.5 μ g/ml) were as follows: CNM-CM-2739, CNM-CM-1369, and CNM-CM-237. In addition, CM-237 was utilized for describing the sequence of the genes *cyp51A* and *cyp51B* (18). *A. flavus* ATCC 204304 and *A. fumigatus* ATCC 204305 were used as quality control strains for susceptibility testing.

Broth microdilution susceptibility testing was performed as described in the NCCLS document M38-P (21) with the modifications described previously (2, 23, 26). ITC (Janssen Pharmaceutical, Madrid, Spain), VRC (Pfizer S.A., Madrid, Spain),

* Corresponding author. Mailing address: Servicio de Micología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Carretera Majadahonda-Pozuelo Km2, 28220 Madrid, Spain. Phone: 34 91 509 7961. Fax: 34 91 509 7966. E-mail: emellado@isciii.es.

TABLE 1. Nucleotide and amino acids substitutions in *cyp51A* and *cyp51B* genes and MICs of azole drugs for *A. fumigatus* clinical and mutant isolates

Isolate (strain) ^b	Nucleotide substitution in indicated codon of gene ^a :					MICs (μg/ml)			
	<i>cyp51A</i>		<i>cyp51B</i>			ITC	VRC	RVC	POS
	54	220	35	387	394				
CM-237	GGG	ATG	TCT	GAT	CCT	0.25	0.5	0.5	0.06
CM-2739	GGG	ATG	TCT	GAT	CCT	0.50	0.5	0.5	0.06
CM-1369	GGG	ATG	TCT	GAT	CCT	0.25	0.5	0.5	0.06
CM-1245 (AF-91)	GGG	⁷²⁹ GTG*	¹⁰⁵ TCC	GAT	CCT	>8.0	1.0	2.0–4.0	0.5–1.0
CM-1252 (AF-90)	GGG	⁷²⁹ GTG*	¹⁰⁵ TCC	GAT	CCT	>8.0	1.0	1.0–2.0	0.5
CM-2158 (AF/1422)	GGG	⁷²⁹ GTG*	¹⁰⁵ TCC	GAT	¹²⁸⁵ CCG	>8.0	1.0	2.0–4.0	0.5–1.0
CM-2159 (F/6919)	GGG	⁷³⁰ AAG**	TCT	GAT	CCT	>8.0	1.0–2.0	1.0–2.0	2.0
CM-2164 (SO/3829)	GGG	⁷³⁰ ACG***	TCT	¹²⁶⁴ GAA	¹²⁸⁵ CCA	>8.0	0.5–1.0	1.0–2.0	0.25–0.5
T-XII	GGG	⁷²⁹ GTG*	TCT	GAT	CCT	>8.0	1.0	2.0	0.5
T-III	GGG	⁷³⁰ AAG**	TCT	GAT	CCT	>8.0	1.0	1.0	2.0
T-IV	GGG	⁷³⁰ AAG**	TCT	GAT	CCT	>8.0	1.0	1.0	1.0
T-VII	GGG	⁷³⁰ AAG**	TCT	GAT	CCT	>8.0	1.0	1.0	1.0
T-XI	GGG	⁷³⁰ AAG**	TCT	GAT	CCT	>8.0	1.0	1.0	1.0
T-XXII	GGG	⁷³⁰ ACG***	TCT	GAT	CCT	>8.0	0.5–1.0	1.0	0.12–0.25

^a Nucleotides are numbered from the translation start codon ATG of *cyp51A* and *cyp51B*. The numbers indicate the position at which a base change occurs (indicated in boldface characters). Asterisks indicate the amino acid substitutions for codon 220: *, M220V; **, M220K; ***, M220T.

^b Transformants T-III, T-VI, T-VII, and T-XI (replacement of mutated *cyp51A* gene copy from CM-2159), T-XII (*cyp51A* from CM-1252), and T-XXII (*cyp51A* copy from CM-2164) are indicated.

RVC (Bristol-Myers Squibb, Madrid, Spain), and POS (Schering-Plough Research Institute, Kenilworth, N.J.) were obtained as powders from their respective manufacturers. The drugs were dissolved in dimethyl sulfoxide (Sigma, Madrid, Spain) at 1,600 μg/ml; the final concentration range assayed was 8.0 to 0.015 μg/ml. Visual readings were performed using a microtiter reading mirror; the MIC was defined as the lowest concentration of drug that completely inhibited fungal growth after 48 h of incubation at 35°C. Susceptibility tests were performed at least twice with each strain on different days. Susceptibility results are shown in Table 1. The five strains exhibited reduced susceptibility to all four triazoles, with various drug MICs depending on the antifungal drug and strain combination; POS was the most active in vitro compound.

PCR amplification and sequence analysis of the *cyp51A* and *cyp51B* genes. Conidia from each strain were inoculated into 3 ml of GYEP broth (2% glucose, 0.3% yeast extract, 1% peptone) and grown overnight at 37°C. Mycelial mats were recovered and subjected to a DNA extraction protocol (18). The full coding sequences of *cyp51A* and *cyp51B* were PCR amplified as previously described (9). To rule out the possibility that any sequence changes identified were due to PCR-induced errors, each mutant was independently analyzed twice.

Sequence analysis of *cyp51A* revealed a number of point mutations. The five ITC-resistant strains (CM-1252, CM-1245, CM-2158, CM-2159, and CM-2164) each had a single nucleotide substitution in codon 220 (encodes methionine), resulting in the introduction of valine, lysine, or threonine (Table 1). The five ITC-resistant strains also harbored point mutations in *cyp51B*; however, two of the three mutations detected were silent, and the one missense mutation (resulting in the replacement of Asp by Glu at codon 387) was not conserved across the five isolates (Table 1). Sequence alignments of the region encompassing M220 revealed that this residue is not an amino acid strictly conserved between all yeasts and moulds, although

this position is conserved in many fungal species and it is on the edge of a highly conserved region (Fig. 1). Moreover, the fact that five ITC-resistant strains harbored the same mutation strongly suggests that the substitution is associated with azole resistance. In this regard, the region encompassing the mutation was sequenced in 22 *A. fumigatus* ITC-susceptible clinical strains; none of the 22 strains had mutations at codon 220.

Replacement of the wild-type *cyp51A* gene with *cyp51A* alleles that encode substitutions at codon 220. The *cyp51A* alleles from strains CM-1252, CM-2159, and CM-2164 were PCR amplified, and each was individually electroporated into the wild-type *A. fumigatus* strain CM-237. Electroporation was carried out using a protocol previously described for *A. nidulans* (28) and subsequently adapted for *A. fumigatus* (31); transformants were selected on medium containing ITC as described previously (9). ITC-resistant transformants appeared after 2 to 7 days of incubation. The transformants were labeled with a “T” followed by a roman numeral (Table 1). The numbers of ITC-resistant transformants obtained using the *cyp51A* genes from strains CM-2159, CM-1252, and CM-2164 were four (T-III, T-VI, T-VII and T-XI), one (T-XII), and one (T-XXII), respectively. To confirm that each transformant contained only one copy of the *cyp51A* gene we performed a Southern blot analysis. Chromosomal DNA was extracted from each transformant, digested with either SalI or BamHI (Amersham Biosciences, Madrid, Spain), and resolved by gel electrophoresis. Southern blots (27) were probed with a labeled fragment of *cyp51A* (18); in every case, only a single band hybridized to the probe (data not shown). The *cyp51A* and *cyp51B* genes from the six transformants were sequenced; all six appeared to have incorporated the mutated *cyp51A* allele. With the exception of the original mutation at codon 220, none of the transformants had any other mutations in either *cyp51A* or *cyp51B*. The susceptibility of the transformants to triazoles was determined as described above; in general, the transfor-




FIG. 1. Alignment of Cyp51 proteins. The figure shows the results of alignment of a segment of Cyp51A (amino acids 205 to 247) (GenBank AAK73659) and Cyp51B (amino acids 220 to 262) (GenBank AAK73660) from *A. fumigatus* with the corresponding CYP51 segments from the following species: *C. albicans* (CaP450; GenBank AAF00598), *C. glabrata* (CaErg11; GenBank AAB02329), *C. tropicalis* (CtErg11; GenBank AAA53284), *Saccharomyces cerevisiae* (ScErg11; GenBank AAA34546), *Schizosaccharomyces pombe* (ScpCyp51; GenBank CAA90803), *C. krusei* (CtErg11; GenBank AAO83898), *Ustilago maydis* (UmErg11; GenBank CAA88176), *Cryptococcus neoformans* (CnErg11; GenBank AAF12370), *Penicillium digitatum* (PdCyp51; GenBank CAD27793), *A. nidulans* (AnCyp51; GenBank AAF79204), *Erysiphe graminis* (EgCyp51; GenBank AAC97606), *Monilinia fructicola* (MfCyp51; GenBank AAL79180), *Venturia inaequalis* (ViCyp51; GenBank AAF71293), *Venturia nashicola* (VnCyp51; GenBank CAC85409), *Leptosphaeria maculans* (LmCyp51; GenBank AAN28927), *Botryotinia fuckeliana* (BfCyp51; GenBank AAF85983), *Neurospora crassa* (NcCyp51; GenBank EAA34813), *Mycosphaerella graminicola* (MgCyp51; GenBank AAF74756), *Tapesia yallundae* (TyErg11; GenBank AAG44831), and *Uncinula necator* (UnCyp51; GenBank AAC49812). The alignment was performed by MegAligne using Clustal V (DNAsstar, Inc.; Lasergene, Madison, Wis.). Asterisks (*) indicate residues located in the F-G loop referred to in the text.

mants exhibited susceptibility profiles similar to those of the original clinical isolates (Table 1).

To identify the gene replacement events we used a direct selection procedure. Consequently, there is a possibility that the mutations identified in the transformants arose spontaneously and were selected through the inclusion of ITC in the transformation plates. However, three observations argue against this possibility. First, the three alleles used in the transformations each encoded a different substitution at residue 220. The mutations identified in the six transformants matched those present in the donor *cyp51A* allele; such congruence would be highly unlikely if the mutations had arisen spontaneously. Second, in control experiments in which the donor DNA was replaced by water, no resistant isolates were detected. Finally, there have been no prior reports of spontaneous mutations arising in this area of the *A. fumigatus* Cyp51A protein in laboratory-selected mutants (16, 20; Manavathu et al., 43rd ICAAC, abstr. M-471).

To date there have been a number of reports that have identified polymorphisms in the *cyp51* gene from clinical *Candida albicans* isolates that are responsible for and/or associated with azole antifungal resistance to fluconazole (10, 17, 29). In some filamentous fungi, one mutation (Y136F) has been correlated with resistance to different demethylase inhibitors (5, 6). In *A. fumigatus*, specific mutations in *cyp51A* have been associated with decreases in susceptibility to ITC and POS (9,

16). In this study, substitutions at residue 220 were detected in five independent ITC-resistant isolates. The minor differences in the ways the mutations impact the susceptibility to specific azoles presumably reflect differences in the ways the azoles interact with the target protein. The clinical significance of these differences, if any, has yet to be determined.

The precise manner in which substitutions at M200 impact triazole binding is not immediately obvious. Recently, a three-dimensional model of 14 α -demethylase from *C. albicans* was built using the crystallographic coordinates of four prokaryotic P450 enzymes (12). The docking of both the substrate and triazoles into the active site of the enzyme was explored. It was postulated that the long side chain of ITC interacted with the residues in the substrate access channel. This channel is lined by hydrophobic and aromatic residues such as F228, I231, F233, V234, and F235 (corresponding to F214, I217, F219, M220, and L221 in Cyp51A from *A. fumigatus*). Some of these residues are predicted to have direct interactions with either the substrate or the antifungal drug (12). From this model the substitutions at methionine 220 might be expected to disrupt drug binding. Recently, a homology model of Cyp51A from *A. fumigatus* was constructed on the basis of the X-ray structure of the CYP51 orthologue from *Mycobacterium tuberculosis* (32). Some of the residues in the predicted *A. fumigatus* Cyp51 F-G loop (T215 and P230) are predicted to have contact with ITC and POS (32) but not directly with VRC. Podust et al. crystal-

lized the *M. tuberculosis* Cyp51 in the presence of fluconazole (25). They suggested that substitutions causing azole resistance in fungi are located in regions of the protein involved in conformational changes associated with the catalytic cycle rather than in residues that directly contact the drug (25). Also, it has been previously pointed out that it seems more important to look at the role of specific residue mutations in relation with their local environments (13). The gathering of further evidence will have to wait until the crystal structure for *A. fumigatus* Cyp51s is obtained in conjunction with the antifungal drugs. In the meantime, the identification of amino acid substitutions responsible for azole resistance continues to provide new insights into the way the drugs interact with Cyp51A. Such knowledge may aid in the development of more active molecules. Further investigations into the functional analysis of the Cyp51A and Cyp51B proteins of *A. fumigatus* are presently in process in our laboratory.

This work was supported in part by grants MPY1120/03 from Instituto de Salud Carlos III and SAF2002-02089 from the Ministry of Science and Technology. E. Mellado held a Ramón y Cajal contract from Ministry of Science and Technology. L. Alcazar-Fuoli has a predoctoral fellowship from Instituto de Salud Carlos III.

We are grateful to J.P. Latge for helpful suggestions. We thank D. W. Denning and J. Mosquera, University of Manchester (United Kingdom), for providing strains AF-90, AF-91, AF-1422, F/6919, and SO/3829 and Gema del Rio for invaluable technical assistance. We thank Pfizer, Janssen Pharmaceutical, Bristol-Myers Squibb, and Schering Plough for supplying antifungal powders. We also thank Paul M. McNicholas (Schering-Plough Research Institute) for critically reading the manuscript and helpful editing suggestions.

REFERENCES

1. Chryssanthou, E. 1997. In vitro susceptibility of respiratory isolates of *Aspergillus* species to itraconazole and amphotericin B. Acquired resistance to itraconazole. *Scand. J. Infect. Dis.* **29**:509–512.
2. Cuenca-Estrella, M., J. L. Rodriguez-Tudela, E. Mellado, J. V. Martinez-Suarez, and A. Monzon. 1998. Comparison of the in vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of *Aspergillus fumigatus*. *J. Antimicrob. Chemother.* **42**:531–533.
3. Dannaoui, E., E. Borel, F. Persat, M. F. Monier, M. A. Piens, et al. 1999. In-vivo itraconazole resistance of *Aspergillus fumigatus* in systemic murine aspergillosis. *J. Med. Microbiol.* **48**:1087–1093.
4. Dannaoui, E., F. Persat, M. F. Monier, E. Borel, M. A. Piens, and S. Picot. 1999. In-vitro susceptibilities of *Aspergillus* spp. isolates to amphotericin B and itraconazole. *J. Antimicrob. Chemother.* **44**:553–555.
5. Délye, C., L. Bousset, and M. F. Corio-Costet. 1998. PCR cloning and detection of point mutations in the eburicol 14 α -demethylase (CYP51) gene from *Erysiphe graminis* f. sp. *hordei*, a “recalcitrant” fungus. *Curr. Genet.* **34**:399–403.
6. Délye, C., F. Laigret, and M. F. Corio-Costet. 1997. A mutation in the 14 α -demethylase gene of *Uncinula necator* that correlates with resistance to a sterol biosynthesis inhibitor. *Appl. Environ. Microbiol.* **63**:2966–2970.
7. Denning, D. W., S. A. Radford, K. L. Oakley, L. Hall, E. M. Johnson, and D. W. Warnock. 1997. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of *Aspergillus fumigatus* infection. *J. Antimicrob. Chemother.* **40**:401–414.
8. Denning, D. W., K. Venkateswarlu, K. L. Oakley, M. J. Anderson, N. J. Manning, D. A. Stevens, D. W. Warnock, and S. L. Kelly. 1997. Itraconazole resistance in *Aspergillus fumigatus*. *Antimicrob. Agents Chemother.* **41**:1364–1368.
9. Diaz-Guerra, T. M., E. Mellado, M. Cuenca-Estrella, and J. L. Rodriguez-Tudela. 2003. A point mutation in the 14 α -sterol demethylase gene *cyp51A* contributes to itraconazole resistance in *Aspergillus fumigatus*. *Antimicrob. Agents Chemother.* **47**:1120–1124.
10. Favre, B., M. Didmon, and N. S. Ryder. 1999. Multiple amino acid substitutions in lanosterol 14 α -demethylase contribute to azole resistance in *Candida albicans*. *Microbiology* **145**:2715–2725.
11. Fortun, J., P. Martin-Davila, M. A. Sanchez, V. Pintado, M. E. Alvarez, A. Sanchez-Sousa, and S. Moreno. 2003. Voriconazole in the treatment of invasive mold infections in transplant recipients. *Eur. J. Clin. Microbiol. Infect. Dis.* **22**:408–413.
12. Ji, H., W. Zhang, Y. Zhou, M. Zhang, J. Zhu, Y. Song, and J. Lu. 2000. A three-dimensional model of lanosterol 14 α -demethylase of *Candida albicans* and its interaction with azole antifungals. *J. Med. Chem.* **43**:2493–2505.
13. Joseph-Horne, T., and D. W. Hollomon. 1997. Molecular mechanisms of azole resistance in fungi. *FEMS Microbiol. Lett.* **149**:141–149.
14. Latgé, J.-P. 1999. *Aspergillus fumigatus* and aspergillosis. *Clin. Microbiol. Rev.* **12**:310–350.
15. Manavathu, E. K., J. A. Vazquez, and P. H. Chandrasekar. 1999. Reduced susceptibility in laboratory-selected mutants of *Aspergillus fumigatus* to itraconazole due to decreased intracellular accumulation of the antifungal agent. *Inter. J. Antimicrob. Agents* **12**:213–219.
16. Mann, P. A., R. M. Parmegiani, S.-Q. Wei, C. A. Mendrick, X. Li, D. Loebenberg, B. DiDomenico, R. S. Hare, S. S. Walker, and P. M. McNicholas. 2003. Mutations in *Aspergillus fumigatus* resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14 α demethylase. *Antimicrob. Agents Chemother.* **47**:577–581.
17. Marichal, P., L. Koymas, S. Willemsens, D. Bellens, P. Verhasselt, W. Luyten, M. Borgers, F. C. S. Ramaekers, F. C. Odds, and H. Vanden Bossche. 1999. Contribution of mutations in the cytochrome P450 14 α -demethylase (Erg11p, Cyp51p) to azole resistance in *Candida albicans*. *Microbiology* **145**:2701–2713.
18. Mellado, E., T. M. Diaz-Guerra, M. Cuenca-Estrella, and J. L. Rodriguez-Tudela. 2001. Identification of two different 14 α -sterol demethylase-related genes (*cyp51A* and *cyp51B*) in *Aspergillus fumigatus* and other *Aspergillus* species. *J. Clin. Microbiol.* **39**:2431–2438.
19. Mosquera, J., and D. W. Denning. 2002. Azole cross-resistance in *Aspergillus fumigatus*. *Antimicrob. Agents Chemother.* **46**:556–557.
20. Nascimento, A. M., G. H. Goldman, S. Park, S. A. Marras, G. Delmas, U. Oza, K. Lolans, M. N. Dudley, P. A. Mann, and D. S. Perlin. 2003. Multiple resistance mechanisms among *Aspergillus fumigatus* mutants with high-level resistance to itraconazole. *Antimicrob. Agents Chemother.* **47**:1719–1726.
21. National Committee for Clinical Laboratory Standards. 1998. Reference method for broth dilution antifungal susceptibility. Testing of filamentous fungi: proposed standard. Document M38-P. National Committee for Clinical Laboratory Standards, Wayne, Pa.
22. Oshero, N., D. P. Kontoyannis, A. Romans, and G. S. May. 2001. Resistant to itraconazole in *Aspergillus nidulans* and *Aspergillus fumigatus* is conferred by extra copies of the *A. nidulans* P-450 14 α -demethylase gene, *pdmA*. *J. Antimicrob. Chemother.* **48**:75–81.
23. Petrikou, E., J. L. Rodriguez-Tudela, M. Cuenca-Estrella, A. Gomez, A. Molleja, and E. Mellado. 2001. Inoculum standardization for antifungal susceptibility testing of filamentous fungi pathogenic for humans. *J. Clin. Microbiol.* **39**:1345–1347.
24. Pfaller, M. A., S. A. Messer, R. J. Hollis, R. N. Jones, et al. 2002. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of *Aspergillus* spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. *Antimicrob. Agents Chemother.* **46**:1032–1037.
25. Podust, L. M., T. L. Poulos, and M. R. Waterman. 2001. Crystal structure of cytochrome P450 14 α -sterol demethylase (CYP51) from *Mycobacterium tuberculosis* in complex with azole inhibitors. *Proc. Natl. Acad. Sci. USA* **98**:3068–3073.
26. Rodriguez-Tudela, J. L., E. Chryssanthou, E. Petrikou, J. Mosquera, D. W. Denning, and M. Cuenca-Estrella. 2003. Interlaboratory evaluation of hematocytometer method of inoculum preparation for testing antifungal susceptibilities of filamentous fungi. *J. Clin. Microbiol.* **41**:5236–5237.
27. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. *Molecular cloning: a laboratory manual*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
28. Sanchez, O., and J. Aguirre. 1996. Efficient transformation of *Aspergillus nidulans* by electroporation of germinated conidia. *Fungal Genet. Newsl.* **43**:48–51.
29. Sanglard, D., F. Ischer, K. Koymans, and J. Bille. 1998. Amino acid substitutions in the cytochrome P450 14 α -demethylase (CYP51A1) from azole-resistant *Candida albicans* clinical isolates contribute to resistance to azole antifungal agents. *Antimicrob. Agents Chemother.* **42**:241–253.
30. Slaven, J. W., M. J. Anderson, D. Sanglard, G. K. Dixon, J. Bille, I. S. Roberts, and D. W. Denning. 2002. Increased expression of a novel *Aspergillus fumigatus* ABC transporter gene, *atrF*, in the presence of itraconazole in an itraconazole resistant clinical isolate. *Fungal Genet. Biol.* **36**:199–206.
31. Weidner, G., C. d'Enfert, A. Koch, P. C. Mol, and A. A. Brakhage. 1998. Development of a homologous transformation system for the human pathogenic fungus *Aspergillus fumigatus* based on the *pyrG* gene encoding orotidine 5'-monophosphate decarboxylase. *Curr. Genet.* **33**:378–385.
32. Xiao, L., V. Madison, A. S. Chau, D. Loebenberg, R. E. Palermo, and P. M. McNicholas. 2004. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14 α -sterol demethylases from *Aspergillus fumigatus* and *Candida albicans* provide insights into posaconazole binding. *Antimicrob. Agents Chemother.* **48**:568–574.